ICTRP Search Portal

Main

Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.

Register:	ClinicalTrials.gov
Last refreshed on:	29 July 2022
Main ID:	NCT02634307
Date of registration:	16/12/2015
Prospective Registration:	No
Primary sponsor:	Biogen
Public title:	A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1
Scientific title:	A Phase 3 Open Label Study to Evaluate the Long-term Safety and Tolerability of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis
Date of first enrolment:	December 10, 2015
Target sample size:	1057
Recruitment status:	Completed
URL:	https://clinicaltrials.gov/show/NCT02634307
Study type:	Interventional
Study design:	Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Phase:	Phase 3

Countries of recruitment
Belgium	Bulgaria	Canada	Germany	Poland	Russian Federation	Serbia	Spain
Ukraine	United States

Contacts

Name:	Medical Director
Address:
Telephone:
Email:
Affiliation:	Biogen

Key inclusion & exclusion criteria

Health Condition(s) or Problem(s) studied

Intervention(s)

Primary Outcome(s)

Secondary Outcome(s)

Secondary ID(s)

Source(s) of Monetary Support

Secondary Sponsor(s)

Ethics review

Results

Results available:	Yes
Date Posted:	24/06/2022
Date Completed:
URL:	https://clinicaltrials.gov/ct2/show/results/NCT02634307

Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.